Cardiopulmonary Exercise Testing Market is predicted to reach USD 1.7 billion at a CAGR of 7.25% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Cardiopulmonary Exercise Testing Market”.

The Cardiopulmonary Exercise Testing market is projected to register a CAGR of 7.25% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Cardiopulmonary Exercise Testing market— Vyaire Medical, Inc (US), MGC Diagnostics Corporation (US), COSMED srl (Italy), CORTEX Biophysik GmbH (Germany), Oxigraf, Inc (US), Koninklijke Philips NV (Netherlands), Hill-Rom Holdings, Inc (US), MEDEV Medical Devices Corporation (Saudi Arabia), and Geratherm Medical AG (Germany), and others.

Global Cardiopulmonary Exercise Testing Market Highlights

The global cardiopulmonary exercise testing market is accounted to register a CAGR of 7.25% during the forecast period and is estimated to reach USD 1.7 billion by 2032.

The growth of the global Cardiopulmonary Exercise Testing market is attributed to the increase in the prevalence of cardiovascular diseases and a rising geriatric population. For instance, according to the UN, by 2050, 1 in 6 people around the globe will be over the age of 65, up from 1 in 11 in 2023. According to the Rural Health Information Hub, in the US, the number of older adults aged 65 and older is expected to grow to almost 90 million by 2050. In addition, by 2030, 1 in 5 Americans is projected to be 65 years old or over. However, the lack of skilled and experienced professionals are anticipated to hamper the market growth.

Access full report @ https://www.marketresearchfuture.com/reports/cardiopulmonary-exercise-testing-market-6626

Segment Analysis

The global Cardiopulmonary Exercise Testing market has been segmented based on product, and end user.

On the basis of product, the global Cardiopulmonary Exercise Testing market has been segmented into CPET metabolic carts and software.

The Cardiopulmonary Exercise Testing market, based on end user, is segmented into hospitals & clinics, diagnostic centers, ambulatory centers, and others. The hospitals & diagnostic centers segment accounted for the largest market with a market share of 63.13% in 2022. One of the major factors contributing to the growth of hospitals & diagnostic centers is that the companies are differentiating their product pipeline to address the challenges while diagnosing. Companies such as Vyaire Medical, Inc (US), MGC Diagnostics Corporation (US) are among the leading firms that have diversified cardiopulmonary exercise testing product portfolios to cater to the medical needs of the consumers.

Regional Analysis

The global cardiopulmonary exercise testing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. The North America further includes US and Canada. The Europe includes countries namely Germany, France, UK, Italy, Spain, and Rest of Europe. The Cardiopulmonary Exercise Testing market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Moreover, the Rest of the World comprises of Middle East, Africa, and Latin America.

North America dominated market in 2022 due to factors such as the the presence of active industry players in the region and the availability of the products propelling the market's growth in North America . According to the American Heart Association, coronary heart disease was one of the leading causes of death in the US in 2020 and account for 41.2% of deaths, followed by stroke (17.3%), other cardiovascular diseases (16.8%), high blood pressure (12.9%), heart failure (9.2%), and artery diseases (2.6%). 

The Europe region shows significant growth during the forecast period. This is due to the rising prevalence of chronic diseases such as cardiovascular diseases, respiratory disorders, and metabolic conditions that is driving the demand for CPET in Europe. CPET provides valuable diagnostic and prognostic information for these conditions, aiding in personalized treatment and management strategies. As per the European Survey of Cardiovascular Disease by Daiichi Sankyo Europe GmbH (Germany), there were approximately 60 million people living with CVD, and 13 million new cases were diagnosed in 2020.

Asia Pacific region is fastest growing region in market in 2022 owing to factors such as the owing to high applications of CPET in the geriatric population as aging populations are more prone to CVDs. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022.

The rest of the world Cardiopulmonary Exercise Testing market is segmented into major regions, namely the Middle East, Africa, and Latin America. The rest of the world region is comprised of the Middle East, Latin America, and Africa. The increasing prevalence of CVDs is an imperative factor to consider for the region’s growth. As per the World Heart Federation, more than 1 million deaths occurred due to CVD in sub-Saharan Africa in 2019. Furthermore, 1.4 million people die each year in the Middle East and North Africa (MENA) region.

Furthermore, rising cases of lung cancer which CPET utilizes in preoperative and postoperative settings for measuring oxygen levels, are another driving factor for market growth. As per GLOBOCAN 2020, the incidence of lung cancer was 45,988 and mortality was 41,171 in both sexes in Africa.

Key Findings of the Study

• The global Cardiopulmonary Exercise Testing market is expected to reach USD 1.7 billion by 2032 at a CAGR of 7.25% during the forecast period.


• The Europe region held the second largest market share of the global market, due to the rising prevalence of chronic diseases such as cardiovascular diseases, respiratory disorders, and metabolic conditions that is driving the demand for CPET in Europe.


• Based on product, the CPET Metabolic Carts held the largest market in 2022.


• Vyaire Medical, Inc (US), MGC Diagnostics Corporation (US), COSMED srl (Italy), CORTEX Biophysik GmbH (Germany), Oxigraf, Inc (US), Koninklijke Philips NV (Netherlands), Hill-Rom Holdings, Inc (US), MEDEV Medical Devices Corporation (Saudi Arabia), and Geratherm Medical AG (Germany), and others are the key players in the market.